Abivax Triggers MACD Death Cross, KDJ Death Cross on 15-Minute Chart
PorAinvest
martes, 21 de octubre de 2025, 2:32 pm ET1 min de lectura
ABVX--
The MACD Death Cross occurs when the MACD line crosses below the signal line, indicating a bearish signal. Similarly, the KDJ Death Cross happens when the KDJ line crosses below the signal line, reinforcing the bearish momentum. These indicators are widely used by technical analysts to predict changes in stock price trends.
Analysts from various financial institutions have initiated coverage on Abivax, with mixed opinions on the stock's potential. On October 13, 2025, Etzer Darout from Barclays initiated coverage on Abivax with an Overweight rating and a $142 price target. However, the recent technical indicators suggest a potential downward trend, which could impact the stock's price.
Investors and financial professionals should closely monitor Abivax's stock performance and consider the implications of these technical indicators. While the Overweight rating from Barclays suggests a potential for growth, the recent technical signals indicate a need for caution.
According to Abivax's 15-minute chart, a MACD Death Cross and KDJ Death Cross were triggered at 14:30 on October 21, 2025. This indicates that the stock price has the potential to continue falling and that the momentum is shifting towards the downside, with a potential for further decreases.
On October 21, 2025, Abivax Société Anonyme (NASDAQ:ABVX) experienced a significant technical shift in its stock price. According to the 15-minute chart, both the MACD (Moving Average Convergence Divergence) and the KDJ (Kaufman Adaptive Moving Average) indicators triggered a "Death Cross" at 14:30. This technical pattern suggests a potential continuation of the downward trend, indicating a shift in momentum towards the downside.The MACD Death Cross occurs when the MACD line crosses below the signal line, indicating a bearish signal. Similarly, the KDJ Death Cross happens when the KDJ line crosses below the signal line, reinforcing the bearish momentum. These indicators are widely used by technical analysts to predict changes in stock price trends.
Analysts from various financial institutions have initiated coverage on Abivax, with mixed opinions on the stock's potential. On October 13, 2025, Etzer Darout from Barclays initiated coverage on Abivax with an Overweight rating and a $142 price target. However, the recent technical indicators suggest a potential downward trend, which could impact the stock's price.
Investors and financial professionals should closely monitor Abivax's stock performance and consider the implications of these technical indicators. While the Overweight rating from Barclays suggests a potential for growth, the recent technical signals indicate a need for caution.
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios